Rock Springs Capital Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Rock Springs Capital Management’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-750,000	Closed	-$35.2M	–	139
2019 Q4	$35.2M	Sell	750,000 -85,000	-10%	-$3.76M	1.11%	28
2019 Q3	$19.7M	Buy	835,000 +31,000	+4%	+$919K	0.79%	49
2019 Q2	$24.2M	Hold	804,000	–	–	0.87%	42
2019 Q1	$18M	Buy	804,000 +54,000	+7%	+$1.16M	0.69%	50
2018 Q4	$13.7M	Hold	750,000	–	–	0.64%	51
2018 Q3	$13.6M	Hold	750,000	–	–	0.49%	65
2018 Q2	$7.46M	Buy	750,000 +150,000	+25%	+$1.04M	0.29%	100
2018 Q1	$3.19M	Hold	600,000	–	–	0.14%	131
2017 Q4	$5.1M	Hold	600,000	–	–	0.23%	107
2017 Q3	$8.76M	Hold	600,000	–	–	0.4%	79
2017 Q2	$11.2M	Sell	600,000 -188,959	-24%	-$4.26M	0.57%	60
2017 Q1	$16.8M	Sell	788,959 -37,041	-4%	-$708K	0.97%	36
2016 Q4	$12.5M	Buy	+826,000	New	+$11.2M	0.84%	40

Other funds holding RARX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Rock Springs Capital Management's RARX Position: Q1 2020 in Review

Rock Springs Capital Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q1 2020, closing a stake of 750,000 shares — an estimated $35.2M sold.

Rock Springs Capital Management first reported a position in RARX in Q4 2016 and held it in 13 quarters. The position peaked at $35.2M in Q4 2019. 144 funds tracked by Wall St. Rank hold RARX as of Q1 2020.

Rock Springs Capital Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Rock Springs Capital Management sold 750,000 Ra Pharmaceuticals, Inc. Common Stock shares in Q1 2020, an estimated $35.2M.
Rock Springs Capital Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 13 quarters.
Rock Springs Capital Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $35.2M in Q4 2019.
144 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q1 2020.

Based on Rock Springs Capital Management's 13F filing for Q1 2020, filed 15 May 2020.